AI Analysis

Log in to generate an AI summary for this stock.

Log in to generate a MOAT report for this stock.

Log in to generate an earnings report for this stock.

Log in to generate an operating leverage report for this stock.

Log in to generate a management report for this stock.

Log in to generate a valuation report for this stock.

CVRx, Inc.

$2.88 -$4.22 (-59.44%)
NASDAQ · 11 Sep 2026 20:00 UTC
Previous Close
$2.86
Day Range
$2.75$2.9
Year Range
$2.2$11.3
Market Cap
76.42M
AVG Volume
657.54K
Trailing/Forward PE
-1.45/-
PEG ratio
0.38
Dividend Yield
-
Next Earnings Date
2026-11-04
Primary Exchange
NASDAQUS
Revenue (USD)
05M10M15M20M24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
CVRX Revenue (USD) by quarter
PeriodRevenue (USD)
26 Q215.71M
26 Q114.77M
25 Q416.02M
25 Q314.69M
25 Q213.59M
25 Q112.35M
24 Q415.34M
24 Q313.37M
24 Q211.81M
24 Q110.77M
Net Income (USD)
-30M-20M-10M024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
CVRX Net Income (USD) by quarter
PeriodNet Income (USD)
26 Q2-14.04M
26 Q1-13.12M
25 Q4-11.93M
25 Q3-12.87M
25 Q2-14.74M
25 Q1-13.77M
24 Q4-10.65M
24 Q3-13.1M
24 Q2-14.03M
24 Q1-22.19M
Operating Income (USD)
-30M-20M-10M024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
CVRX Operating Income (USD) by quarter
PeriodOperating Income (USD)
26 Q2-13.02M
26 Q1-12.16M
25 Q4-11.18M
25 Q3-12.27M
25 Q2-14.38M
25 Q1-13.44M
24 Q4-10.27M
24 Q3-13.01M
24 Q2-13.97M
24 Q1-22.23M
EBITDA (USD)
-30M-20M-10M024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
CVRX EBITDA (USD) by quarter
PeriodEBITDA (USD)
26 Q2-12.05M
26 Q1-11.36M
25 Q4-10.34M
25 Q3-11.2M
25 Q2-13.07M
25 Q1-12.13M
24 Q4-9.02M
24 Q3-11.93M
24 Q2-12.89M
24 Q1-21.06M
Cash Flows (USD)
-15M-10M-5M024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
CVRX Cash Flows (USD) by quarter
PeriodCash Flows (USD)
26 Q2-8.94M
26 Q1-12.29M
25 Q4-9.83M
25 Q3-10M
25 Q2-8.04M
25 Q1-12.88M
24 Q4-8.06M
24 Q3-10.45M
24 Q2-10.19M
24 Q1-11.81M
EPS (USD)
-1.5-1-0.5024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
CVRX EPS (USD) by quarter
PeriodEPS (USD)
26 Q2-0.53
26 Q1-0.5
25 Q4-0.46
25 Q3-0.49
25 Q2-0.57
25 Q1-0.53
24 Q4-0.43
24 Q3-0.57
24 Q2-0.65
24 Q1-1.04
Expenses (USD)
010M20M30M40MR&DSG&ACapex24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
CVRX Expenses (USD) by quarter
PeriodExpenses (USD)
26 Q226.86M
26 Q125.16M
25 Q425.08M
25 Q325.12M
25 Q225.74M
25 Q123.86M
24 Q423.37M
24 Q324.17M
24 Q224.09M
24 Q132.17M
Cash & Debt (USD)
050M100M150MCashLong Term DebtShort Term Debt24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
CVRX Cash & Debt (USD) by quarter
PeriodCash & Debt (USD)
26 Q264.59M
26 Q172.3M
25 Q475.71M
25 Q385.12M
25 Q295.03M
25 Q1102.67M
24 Q4105.93M
24 Q3100.16M
24 Q270.4M
24 Q180.11M
Debt ratios
00.511.524 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
CVRX Debt ratios by quarter
PeriodDebt ratios
26 Q20.12
26 Q10.28
25 Q40.53
25 Q30.76
25 Q20.96
25 Q11.14
24 Q41.01
24 Q30.92
24 Q20.79
24 Q11.01
Margins
0%25%50%75%100%24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
CVRX Margins by quarter
PeriodMargins
26 Q287.39%
26 Q187.22%
25 Q486.28%
25 Q385.49%
25 Q282.84%
25 Q183.51%
24 Q485.01%
24 Q383.19%
24 Q282.71%
24 Q183.79%
Return on Capital
-80%-60%-40%-20%0%24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
CVRX Return on Capital by quarter
PeriodReturn on Capital
26 Q2-70.39%
26 Q1-45.07%
25 Q4-30.35%
25 Q3-26.78%
25 Q2-25.44%
25 Q1-19.85%
24 Q4-14.99%
24 Q3-20.1%
24 Q2-25.39%
24 Q1-33.48%
Shares Outstanding
010M20M30M24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
CVRX Shares Outstanding by quarter
PeriodShares Outstanding
26 Q226.52M
26 Q126.36M
25 Q426.22M
25 Q326.17M
25 Q226.07M
25 Q125.88M
24 Q422.6M
24 Q322.78M
24 Q221.63M
24 Q121.23M
Book Value Per Share (USD)
0123424 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
CVRX Book Value Per Share (USD) by quarter
PeriodBook Value Per Share (USD)
26 Q20.75
26 Q11.1
25 Q41.5
25 Q31.84
25 Q22.22
25 Q12.68
24 Q43.14
24 Q32.86
24 Q22.55
24 Q13.12
Total Assets (USD)
050M100M150M24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
CVRX Total Assets (USD) by quarter
PeriodTotal Assets (USD)
26 Q292.28M
26 Q199.73M
25 Q4104.79M
25 Q3111.33M
25 Q2119.56M
25 Q1129.59M
24 Q4133.41M
24 Q3127.67M
24 Q295.98M
24 Q1106.17M
Employee Count
010020030020212022202320242025
CVRX Employee Count by quarter
PeriodEmployee Count
2025223
2024206
2023200
2022160
2021109
Free Cash Flow Yield
-80%-60%-40%-20%0%med -20.05%Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
CVRX Free Cash Flow Yield by quarter
PeriodFree Cash Flow Yield
Sep 26-53.76%
Sep 26-50.76%
Aug 26-52.48%
Aug 26-54.52%
Aug 26-50.27%
Aug 26-64.78%
Jul 26-29.41%
Jul 26-32.14%
Jul 26-31.03%
Jul 26-28.06%
Jul 26-27.21%
Jun 26-26%
Jun 26-30.78%
Jun 26-30.29%
Jun 26-28.32%
May 26-27.3%
May 26-24.94%
May 26-25.44%
May 26-22.76%
May 26-19.5%
Apr 26-20.13%
Apr 26-21.12%
Apr 26-21.71%
Apr 26-17.25%
Mar 26-17.44%
Mar 26-17.89%
Mar 26-20.64%
Mar 26-18.84%
Feb 26-19.05%
Feb 26-25.44%
Feb 26-31.4%
Feb 26-22.74%
Jan 26-21.75%
Jan 26-20.38%
Jan 26-28.59%
Jan 26-18.37%
Jan 26-20.98%
Dec 25-20.08%
Dec 25-18.55%
Dec 25-17.63%
Dec 25-16.46%
Nov 25-15.19%
Nov 25-15.12%
Nov 25-16.07%
Nov 25-15.34%
Oct 25-14.84%
Oct 25-14.47%
Oct 25-15.2%
Oct 25-16.9%
Oct 25-17.36%
Sep 25-20.03%
Sep 25-21.09%
Sep 25-19.22%
Sep 25-19.34%
Aug 25-19.26%
Aug 25-19.39%
Aug 25-21.51%
Aug 25-20.89%
Aug 25-21.25%
Jul 25-19.26%
Jul 25-20.08%
Jul 25-23.52%
Jul 25-24.42%
Jun 25-27.61%
Jun 25-27.42%
Jun 25-27.42%
Jun 25-24.49%
May 25-24.2%
May 25-24.09%
May 25-25.34%
May 25-33.68%
May 25-22.55%
Apr 25-26.64%
Apr 25-28.68%
Apr 25-28.77%
Apr 25-15.29%
Mar 25-14.35%
Mar 25-14.35%
Mar 25-15.67%
Mar 25-15.49%
Feb 25-13.83%
Feb 25-12.94%
Feb 25-11.77%
Feb 25-12.13%
Jan 25-11.11%
Jan 25-9.99%
Jan 25-10.08%
Jan 25-12.53%
Jan 25-13.02%
Dec 24-13.48%
Dec 24-14.66%
Dec 24-13.84%
Dec 24-13.17%
Nov 24-11.59%
Nov 24-11.96%
Nov 24-12.76%
Nov 24-11.44%
Nov 24-13.25%
Oct 24-17.53%
Oct 24-18.6%
Price to Sales
0246810med 3.69Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
CVRX Price to Sales by quarter
PeriodPrice to Sales
Sep 261.25
Sep 261.32
Aug 261.28
Aug 261.23
Aug 261.33
Aug 261.04
Jul 262.31
Jul 262.11
Jul 262.19
Jul 262.42
Jul 262.5
Jun 262.61
Jun 262.21
Jun 262.24
Jun 262.4
May 262.49
May 262.73
May 262.67
May 263.16
May 263.69
Apr 263.57
Apr 263.41
Apr 263.31
Apr 264.17
Mar 264.12
Mar 264.02
Mar 263.48
Mar 263.82
Feb 263.78
Feb 262.83
Feb 262.29
Feb 263.06
Jan 263.2
Jan 263.42
Jan 262.44
Jan 263.79
Jan 263.32
Dec 253.47
Dec 253.75
Dec 253.95
Dec 254.23
Nov 254.59
Nov 254.61
Nov 254.33
Nov 254.54
Oct 254.86
Oct 254.99
Oct 254.75
Oct 254.27
Oct 254.16
Sep 253.6
Sep 253.42
Sep 253.75
Sep 253.73
Aug 253.74
Aug 253.72
Aug 253.35
Aug 253.45
Aug 253.7
Jul 254.08
Jul 253.92
Jul 253.34
Jul 253.22
Jun 252.85
Jun 252.87
Jun 252.87
Jun 253.21
May 253.25
May 253.26
May 253.1
May 252.33
May 253.5
Apr 252.96
Apr 252.75
Apr 252.74
Apr 255.16
Mar 255.5
Mar 255.5
Mar 255.04
Mar 255.1
Feb 255.71
Feb 256.1
Feb 257.28
Feb 257.06
Jan 257.7
Jan 258.57
Jan 258.5
Jan 256.83
Jan 256.58
Dec 246.35
Dec 245.84
Dec 246.19
Dec 246.5
Nov 247.39
Nov 247.16
Nov 246.71
Nov 247.48
Nov 246.46
Oct 244.91
Oct 244.62
Price to Book
02468med 4.26Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
CVRX Price to Book by quarter
PeriodPrice to Book
Sep 263.83
Sep 264.05
Aug 263.92
Aug 263.77
Aug 264.09
Aug 263.18
Jul 264.69
Jul 264.29
Jul 264.45
Jul 264.92
Jul 265.07
Jun 265.31
Jun 264.48
Jun 264.55
Jun 264.87
May 265.05
May 265.53
May 265.42
May 264.55
May 265.31
Apr 265.15
Apr 264.91
Apr 264.77
Apr 266.01
Mar 265.94
Mar 265.79
Mar 265.02
Mar 265.5
Feb 265.44
Feb 264.07
Feb 263.3
Feb 263.57
Jan 263.73
Jan 263.98
Jan 262.84
Jan 264.42
Jan 263.87
Dec 254.04
Dec 254.37
Dec 254.6
Dec 254.93
Nov 255.34
Nov 255.36
Nov 255.05
Nov 255.29
Oct 254.59
Oct 254.7
Oct 254.48
Oct 254.03
Oct 253.92
Sep 253.4
Sep 253.23
Sep 253.54
Sep 253.52
Aug 253.53
Aug 253.51
Aug 253.16
Aug 253.26
Aug 252.82
Jul 253.11
Jul 252.98
Jul 252.55
Jul 252.45
Jun 252.17
Jun 252.19
Jun 252.19
Jun 252.45
May 252.48
May 252.49
May 252.37
May 251.78
May 252.53
Apr 252.14
Apr 251.99
Apr 251.98
Apr 253.73
Mar 253.97
Mar 253.97
Mar 253.64
Mar 253.68
Feb 254.12
Feb 254.4
Feb 255.27
Feb 255.12
Jan 255.59
Jan 256.21
Jan 256.16
Jan 254.95
Jan 254.77
Dec 244.6
Dec 244.23
Dec 244.48
Dec 244.71
Nov 245.35
Nov 245.19
Nov 244.86
Nov 245.42
Nov 244.68
Oct 243.94
Oct 243.72
CVRx, Inc.
CVRX
Stockpicker

Video analysis: CVRX

All videos

No video analysis for this stock yet. Request one from our team.

Your email is used only to follow up on this request. We do not add you to marketing lists. Privacy Policy

News: CVRX

HAGENS BERMAN, NATIONAL SECURITIES LAW FIRM, Encourages CVRx Inc. (CVRX) Investors with Substantial Losses to Contact Firm: Investigating Potential Securities Fraud Following 59% Stock Drop

prnewswire.com · 10 Sep 2026

HAGENS BERMAN, NATIONAL SECURITIES LAW FIRM, Encourages CVRx Inc. (CVRX) Investors with Substantial Losses to Contact Firm: Investigating Potential Securities Fraud Following 59% Stock Drop

SAN FRANCISCO, Sept. 10, 2026 /PRNewswire/ -- Hagens Berman, a national shareholder rights litigation firm, announces it has opened an investigation into CVRx Inc. (NASDAQ: CVRX) regarding potential violations of federal securities laws.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CVRx, Inc. - CVRX

prnewswire.com · 3 Sep 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CVRx, Inc. - CVRX

NEW YORK, Sept. 3, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of CVRx, Inc. ("CVRx" or the "Company") (NASDAQ: CVRX).

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CVRx, Inc. - CVRX

globenewswire.com · 1 Sep 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CVRx, Inc. - CVRX

NEW YORK, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of CVRx, Inc. (“CVRx” or the “Company”) (NASDAQ: CVRX).

CVRx Secures Devoted Health Coverage for Barostim Therapy

zacks.com · 28 Aug 2026

CVRx Secures Devoted Health Coverage for Barostim Therapy

CVRX secures Devoted Health Medicare Advantage coverage for Barostim, expanding reimbursement access to about 466,000 members across 29 states.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims

prnewswire.com · 27 Aug 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims

On Behalf of Investors of CVRx, Inc. - CVRX NEW YORK, Aug. 27, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of CVRx, Inc. ("CVRx" or the "Company") (NASDAQ: CVRX).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

HAGENS BERMAN, NATIONAL SECURITIES LAW FIRM, Encourages CVRx Inc. (CVRX) Investors with Substantial Losses to Contact Firm: Investigating Potential Securities Fraud Following 59% Stock Drop

prnewswire.com · 26 Aug 2026

HAGENS BERMAN, NATIONAL SECURITIES LAW FIRM, Encourages CVRx Inc. (CVRX) Investors with Substantial Losses to Contact Firm: Investigating Potential Securities Fraud Following 59% Stock Drop

SAN FRANCISCO, Aug. 26, 2026 /PRNewswire/ -- Hagens Berman, a national shareholder rights litigation firm, announces it has opened an investigation into CVRx Inc. (NASDAQ: CVRX) regarding potential violations of federal securities laws. The investigation follows disclosures of a U.S. Department of Justice Civil Investigative Demand ("CID"), severe cuts to revenue guidance, commercial sales force disruption, and the sudden termination of the company's Chief Revenue Officer.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CVRx, Inc. - CVRX

globenewswire.com · 25 Aug 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CVRx, Inc. - CVRX

NEW YORK, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of CVRx, Inc. (“CVRx” or the “Company”) (NASDAQ: CVRX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

CVRx Responds to Letter from Pointillist Family Office

globenewswire.com · 25 Aug 2026

CVRx Responds to Letter from Pointillist Family Office

MINNEAPOLIS, Aug. 25, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today issued the following statement in response to the public letter to CVRx's Board of Directors from Jorey Chernett at Pointillist Family Office, dated August 24, 2026: The Board of Directors and leadership team are committed to acting in the best interests of all CVRx shareholders and regularly evaluate a full range of options to maximize value for all shareholders. The Board values all shareholder input and appreciates the open dialogue the Company has maintained with Mr.

Similar companies

Disclaimer: The historical data presented on this platform is provided by Financial Modeling Prep. Stock Picker is a platform for informational purposes only and does not provide financial advice. Users are encouraged to conduct their own research and consult with a qualified financial advisor before making investment decisions.